Last reviewed · How we verify
Follitropin Delta, Recombinant
At a glance
| Generic name | Follitropin Delta, Recombinant |
|---|---|
| Sponsor | IVI Madrid |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Optimal Stimulation of Hypo-responders Undergoing in Vitro Fertilization (IVF) (PHASE4)
- Real-world Evidence on Follitropin Delta Individual Dosing
- Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women (PHASE3)
- The Pharmacokinetic and Bioavailability of GenSci094 Before and After a Change in Manufacturing Site (PHASE1)
- Dysregulation of FSH in Obesity: Functional and Statistical Analysis (NA)
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2) (PHASE3)
- Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1) (PHASE3)
- A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Follitropin Delta, Recombinant CI brief — competitive landscape report
- Follitropin Delta, Recombinant updates RSS · CI watch RSS
- IVI Madrid portfolio CI